Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:4948
Name gallbladder carcinoma
Definition A gallbladder cancer that has_material_basis_in abnormally proliferating cells derives_from epithelial cells.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer organ system cancer gastrointestinal system cancer hepatobiliary system cancer biliary tract cancer gallbladder cancer gallbladder carcinoma

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
ATM S1905Ifs*25 Olaparib gallbladder carcinoma predicted - sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT01174121 Phase II Pembrolizumab Cyclophosphamide + Fludarabine Aldesleukin Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer Recruiting USA 0
NCT02042443 Phase II Fluorouracil + Leucovorin Capecitabine Trametinib Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery Completed USA 0
NCT02115542 Phase II Regorafenib Single Agent Regorafenib in Refractory Advanced Biliary Cancers Completed USA 0
NCT02151084 Phase II Cisplatin + Gemcitabine + Selumetinib A Study of Different Dosing Schedules of Selumetinib With Cisplatin/Gemcitabine (CIS/GEM) Versus CIS/GEM Alone in Biliary Cancer Active, not recruiting CAN 0
NCT02631590 Phase II Cisplatin + Copanlisib + Gemcitabine Copanlisib (BAY 80-6946) in Combination With Gemcitabine and Cisplatin in Advanced Cholangiocarcinoma Completed USA 0
NCT02829918 Phase II Nivolumab Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers Active, not recruiting USA 0
NCT03260712 Phase II Cisplatin + Gemcitabine + Pembrolizumab Pembrolizumab in Biliary Tract Cancer Active, not recruiting ESP | DEU 1
NCT03704480 Phase II Durvalumab + Tremelimumab Durvalumab Plus Tremelimumab Combination Immunotherapy With or Without Weekly Paclitaxel in Patients With Advanced Biliary Tract Carcinoma (BTC) After Failure of Platinum-based Chemotherapy (IMMUNO-BIL) Recruiting FRA 0
NCT04003896 Phase II Abemaciclib A Study to Evaluate Abemaciclib in Advanced Biliary Tract Carcinoma Who Failed Prior First Line Therapy Recruiting USA 0
NCT04068194 Phase Ib/II Avelumab Avelumab + Peposertib Testing the Combination of New Anti-cancer Drug Nedisertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies Recruiting USA 0
NCT04137289 Phase I BI 905711 A First-in-human Phase Ia/b, Open Label, Multicentre, Dose Escalation Study of BI 905711 in Patients With Advanced Gastrointestinal Cancers Recruiting USA | ESP | DEU 2
NCT04203160 Phase Ib/II Cisplatin + Gemcitabine Cisplatin + CPI-613 + Gemcitabine Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04) Recruiting USA 0
NCT04430738 Phase Ib/II Pembrolizumab + Trastuzumab + Tucatinib Fluorouracil + Leucovorin + Oxaliplatin + Trastuzumab + Tucatinib Capecitabine + Oxaliplatin + Pembrolizumab + Trastuzumab + Tucatinib Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab + Trastuzumab + Tucatinib Capecitabine + Oxaliplatin + Trastuzumab + Tucatinib Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers Recruiting USA 0
NCT04677504 Phase II Atezolizumab + Cisplatin + Gemcitabine Atezolizumab + Bevacizumab + Cisplatin + Gemcitabine A Study of Atezolizumab With or Without Bevacizumab in Combination With Cisplatin Plus Gemcitabine in Patients With Untreated, Advanced Biliary Tract Cancer Active, not recruiting USA | ITA | ESP 10
NCT04941287 Phase II Atezolizumab + Varlilumab Atezolizumab + Cobimetinib + Varlilumab Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of A Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract Cancer Recruiting USA 0
NCT04969887 Phase II Ipilimumab + Nivolumab Combination Immunotherapy in Rare Cancers Under InvesTigation (MOST-CIRCUIT) Recruiting 1